KLCM
ACTU

KG&L Capital Management’s Actuate Therapeutics ACTU Stock Holding History

KG&L Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,000
Closed -$81.2K – 214
2025
Q1 		$81.2K Hold
12,000
– – 0.03% 190
2024
Q4 		$95.5K Hold
12,000
– – 0.03% 183
2024
Q3 		$89.4K Buy
+12,000
New +$95K 0.03% 186

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

KG&L Capital Management's ACTU Position: Q2 2025 in Review

KG&L Capital Management sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 12,000 shares — an estimated $81.2K sold.

KG&L Capital Management first reported a position in ACTU in Q3 2024 and held it in 3 quarters. The position peaked at $95.5K in Q4 2024. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

  • KG&L Capital Management reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • KG&L Capital Management sold 12,000 Actuate Therapeutics shares in Q2 2025, an estimated $81.2K.
  • KG&L Capital Management first reported a position in Actuate Therapeutics in Q3 2024 and held it in 3 quarters.
  • KG&L Capital Management's Actuate Therapeutics position peaked at $95.5K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on KG&L Capital Management's 13F filing for Q2 2025, filed 17 Jul 2025.